FED Fear Factor Fades then Biotechs Rally: AMGN,IBB…Update-1 Bearish Reversal
Update-1... 9/13... Hard to Call Next Move: Macro and i Rates Rule The market was rattled at the opening with the IEA news on cuts in the demand forecast for crude which dropped 2.33%. Subsequently FED hike fears returned causing more volatility with stocks and significantly a major move up in...
Biotechs Eke Out Gains On Product Pipeline News…Update-2
Update-2...Market rallies Monday after 2% sell-off on Friday IBB held support at $280, up 1.9% today to 284 as of mid-morning . Mid-caps and large caps strong. ------ Update-1... FED Rate Increase Fear Sparks Sell-Off NASDAQ down 1.14%, 10 Year Bond 1.67%, IBB down 1.4%, XBI down 1.64%... 11:30...
Deal of the Day: Cepheid (CPHD) Sells Out to Danaher (DHR) for $4B
M&A Deal of the Day: Cepheid (CPHD) up 50% Over Friday Close on Cash Buyout We have been spending too much time on biopharma. It is time to dust off our Dx and Tools portfolio, which is on hold, and find some value stocks for Q4 moves. We did an update in Q4 of 2015 on Molecular Diagnostics...
Healthcare Stocks Lag Market on Drug Pricing…Update-2
Update-2... 945 am EDT...Biotechs Hold Support IBB up 1.55% to $285 holding support at $280; XBI up 2.99% to $61.95 holding support at $60. Update-1...More Fallout from Mylan (MYL) EpiPen Drug Pricing MYL stock was down over 4% today on news that the EpiPen was mis-classified as a generic drug...
Biotech Investors Stung By Drug Pricing Flap…Update-1
Update-1... IBB Trying to hold the $280 line after media bashing of EpiPen Pricing- now they have a generic EpiPen for half the price! Biotech outflows are a concern (-$184M) Gilead Sciences (GILD) down 2.89% on new potential competition from GlaxoSmithK (GSK) HIV double therapy drug with cost...